960 x 350_41

In Vitro Metabolism

The ADME assay development pipeline includes in vitro ADME assays that are necessary once a lead candidate has been selected. The safety profile of a drug candidate will depend partly on its interactions with other drugs, especially those that may be administered concomitantly in standard-of-care treatment. Assessing the risks of possible drug-interactions using validated bioanalytical methods is thus an essential early step in the candidate development process. Q2 Solutions offers a suite of in vitro assays to support drug-drug interaction testing, including cytochrome P450 (CYP) enzyme inhibition (IC50), time-dependent CYP inhibition, induction of CYP enzymes, and CYP reaction phenotyping. All in vitro metabolism assay results are presented in fully QC-reviewed, regulatory-style reports to support filing of IND applications.

Assessing Drug-Drug Interaction Risks

Drug-drug interaction testing provides a definitive assessment of these risks and should be performed early after selection of a lead candidate

Learn more
Q2-Header_1280x350_2

Related Thought Leaders Insights


Innovation Laboratories

Q2 Solutions Innovation Laboratories is located in the heart of the dynamic Research Triangle Park and within our global headquarters in Durham, NC, USA. This facility creates an innovative...

The potential of applying Flow Cytometry as an IVD technology for CDx

In this episode, Megan McCausland, Scientific Advisor for Flow Cytometry at Q2 Solutions, and Scott Bornheimer, Associate Director of Medical and Scientific Affairs at BD Biosciences, discuss the...

Translational Science and Innovation Laboratory (TSAIL)

Located in the heart of the Research Triangle Park, Q2 Solutions’ state-of-the-art Translational Science and Innovation Laboratory (TSAIL) is designed for exploratory biomarker research and new...